Drug transporters and renal drug disposition in the newborn

References

• Zhou S F, Liu J P, Chowbay B. Polymorphism of human cytochrome P450 enzymes and its clinical impact. Drug Metab Rev 2009; 41: 89–295
   PubMed Web of Science ®Google Scholar
• Maeda K, Sugiyama Y. Impact of genetic polymorphisms of transporters on the pharmacokinetic, pharmacodynamic and toxicological properties of anionic drugs. Drug Metab Pharmacokinet 2008; 23: 223–235
   PubMed Web of Science ®Google Scholar
• Kapur G, Mattoo T, Aranda J V. Pharmacogenomics and renal drug disposition in the newborn. Semin Perinatol 2004; 28: 132–140
   PubMed Web of Science ®Google Scholar
• Maeda K, Ieiri I, Yasuda K, Fujino A, Fujiwara H, Otsubo K, Hirano M, Watanabe T, Kitamura Y, Kusuhara H, et al. Effects of organic anion transporting polypeptide 1B1 haplotype on pharmacokinetics of pravastatin, valsartan, and temocapril. Clin Pharmacol Ther 2006; 79: 427–439
   PubMed Web of Science ®Google Scholar
• Sweet D H, Pritchard J B. Localization of an organic anion transporter-GFP fusion construct (rROAT1-GFP) in intact proximal tubules. Am J Physiol: Renal Physiol 1999; 276: F864–F873
   PubMed Web of Science ®Google Scholar
• Sweet D H, Bush K T, Nigam S K. The organic anion transporter family: from physiology to ontogeny and the clinic. Am J Physiol: Renal Physiol 2001; 281: F197–F205
   PubMed Web of Science ®Google Scholar
• Sweet D H, Wolff N A, Pritchard J B. Expression cloning and characterization of ROAT1. The basolateral organic anion transporter in rat kidney. J Biol Chem 1997; 272: 30088–30095
   PubMed Web of Science ®Google Scholar
• Sweet D H, Chan L MS, Walden R, Yung X, Miller D S, Pritchard J B. Organic Anion Transporter 3 [Slc22a8] is a dicarboxylate exchanger indirectly coupled to the Na+ gradient. Am J Physiol: Renal Physiol 2003; 284: F763–F769
   PubMed Web of Science ®Google Scholar
• Enomoto A, Takeda M, Shimoda M, Narikawa S, Kobayashi Y, Yamamoto T, Sekine T, Cha S H, Niwa T, Endou H. Interaction of human organic anion transporters 2 and 4 with organic anion transport inhibitors. J Pharmacol Exp Ther 2002; 301: 797–802
   PubMed Web of Science ®Google Scholar
• Kobayashi Y, Ohshiro N, Shibusawa A, Sasaki T, Tokuyama S, Sekine T, Endou H, Yamamoto T. Isolation, characterization and differential gene expression of multispecific organic anion transporter 2 in mice. Mol Pharmacol 2002; 62: 921–926
   PubMed Web of Science ®Google Scholar
• Sekine T, Cha S H, Tsuda M, Apiwattanakul N, Nakajima Y, Endou H. Identification of multispecific organic anion transporter 2 expressed predominantly in the liver. FEBS Lett 1998; 429: 179–182
   PubMed Web of Science ®Google Scholar
• Miller D S, Stewart D E, Pritchard J B. Intracellular compartmentation of organic anions within renal cells. Am J Physiol 1993; 264: R882–R890
   PubMed Web of Science ®Google Scholar
• Sweet D H. Organic anion transporter (Slc22a) family members as mediators of toxicity. Toxicol Appl Pharmacol 2005; 204: 198–215
   PubMed Web of Science ®Google Scholar
• Ueda K, Cardarelli C, Gottesman M M, Pastan I. Expression of a full length cDNA for the human MDR1’ gene confers resistance to colchicine, doxorubicin, and vinblastine. Proc Natl Acad Sci USA 1987; 84: 3004–3008
   PubMed Web of Science ®Google Scholar
• Regev R, Katzir H, Yeheskely D, et al. Modulation of P-glycoprotein-mediated multidrug resistance by acceleration of passive drug permeation across the plasma membrane. FEBS J 2007; 274: 6204–6214
   PubMed Web of Science ®Google Scholar
• Toshihisa I, Onishi Y, Hirano H, Oosumi K, Nagakura M, Taruib S. Pharmacogenomics of Drug Transporters: a new approach to functional analysis of the genetic polymorphisms of ABCB1 (P-glycoprotein/MDR1). Biol Pharm Bull 2004; 27: 939–948
   PubMed Web of Science ®Google Scholar
• Petzinger E, Geyer J. Drug transporters in pharmacokinetics. Naunyn-Schmiedeberg's Arch Pharmacol 2006; 372: 465–475
   Google Scholar
• Komar A A. Silent SNPs: impact on gene function and phenotype. Pharmacogenomics 20078; 1075–1080
   PubMed Web of Science ®Google Scholar
• Hoffmeyer S, Burk O, von Richter O, Arnold H P, Brockmöller J, Johne A, Cascorbi I, Gerloff T, Roots I, Eichelbaum M, et al. Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and activity in vitro. Proc Nat Acad Sci USA 2000; 97: 3473–3478
   PubMed Web of Science ®Google Scholar
• Drescher S, Schaeffeler E, Hitzl M, Hofmann U, Schwab M, Brinkmann U, Eichelbaum M, Fromm M F. MDR1 gene polymorphisms and disposition of the P-glycoprotein substrate fexofenadine. Br J Clin Pharmacol 2002; 53: 526–534
   PubMed Web of Science ®Google Scholar
• Fromm M F. Genetically determined differences in P-glycoprotein function: implications for disease risk. Toxicology 2002; 181/182: 299–303
   Web of Science ®Google Scholar
• Atanasova Svon Ahsen N, Dimitrov T, Armstrong V, Oellerich M, Toncheva D. MDR1 haplotypes modify BEN disease risk: a study in Bulgarian patients with Balkan endemic nephropathy compared to healthy controls. Nephron Exp Nephrol 2004; 96: e7–e13
   Google Scholar
• Kafka A, Sauer G, Jaeger C, Grundmann R, Kreienberg R, Zeillinger R, Deissler H. Polymorphism C3435T of the MDR-1 gene predicts response to preoperative chemotherapy in locally advanced breast cancer. Int J Oncol 2003; 22: 1117–1121
   PubMed Web of Science ®Google Scholar
• Juyal G, Midha V, Amre D, Sood A, Seidman E, Thelma B K. Associations between common variants in the MDR1 (ABCB1) gene and ulcerative colitis among North Indians. Pharmacogenet Genomics 2009; 19: 77–85
   PubMed Web of Science ®Google Scholar
• Kim R B. 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors (statins) and genetic variability (single nucleotide polymorphisms) in a hepatic drug uptake transporter: what's it all about. Clin Pharmacol Ther 2004; 75: 381–385
   PubMed Web of Science ®Google Scholar
• Niemi M, Kivistö K T, Hofmann U, Schwab M, Eichelbaum M, Fromm M. Fexofenadine pharmacokinetics are associated with a polymorphism of the SCLO1B1 gene (encoding OATP1B1). Br J Clin Pharmacol 2005; 59: 602–604
   PubMed Web of Science ®Google Scholar
• Iida A, Saito S, Sekine A, Mishima C, Kondo K, Kitamura Y, Harigae S, Osawa S, Nakamura Y. Catalog of 258 single nucleotide polymorphisms (SNPs) in genes encoding three organic anion transporters, three organic anion transporting polypeptides, and three NADH: ubichinone oxidoreductase flavoproteins. J Hum Genet 2001; 46: 668–683
   PubMed Web of Science ®Google Scholar
• Jungbluth G L, Welshman I R, Hopkins N K. Linezolid pharmacokinetics in pediatric patients: an overview. Pediatr Infect Dis J 2003; 22: S153–S157
   PubMed Web of Science ®Google Scholar
• Drukker A, Guignard J P. Renal aspects of the term and preterm infant: a selective update. Curr Opin Pediatr 2002; 14: 175–182
   PubMed Web of Science ®Google Scholar
• Vanpee M, Blennow Linnie T, Vanpée M, Blennow M, Linné T, Herin P, Aperia A. Renal function in very low birth weight infants: normal maturity reached during early childhood. J Pediatr 1992; 121: 784–788
   PubMed Web of Science ®Google Scholar
• Nagourney B A, Aranda J V. Physiologic differences of clinical significance. Fetal and neonatal physiology, 2nd ed, R A Polin, W W Fox. Saunders, Philadelphia, PA 1998; 239–249
   Google Scholar
• Ward R M. Drug disposition in the late preterm (“near-term”) newborn. Semin Perinatol 2006; 30: 48–51
   PubMed Web of Science ®Google Scholar
• Nouws J F. Pharmacokinetics in immature animals: a review. J Anim Sci 1992; 70: 3627–3634
   PubMed Web of Science ®Google Scholar
• Braunlich H. Hormonal control of postnatal development of renal tubular transport of weak organic acids. Pediatr Nephrol 1988; 2: 151–155
   PubMed Web of Science ®Google Scholar
• Yaffe S J, Aranda J V, Kauffman R E. Neonatal and pediatric pharmacology: therapeutic principles in practice3rd ed. Lippincott Williams & Wilkins, Philadelphia 2005; 20–31, Chapter 3
   Google Scholar
• Chen N, Aleksa K, Woodland C, Rieder M, Koren G. Ontogeny of drug elimination by the human kidney. Pediatr Nephrol 2006; 21: 160–168
   PubMed Web of Science ®Google Scholar
• Buist S C, Cherrington N J, Choudhuri S, Hartley D P, Klaassen C D. Gender-specific and developmental influences on the expression of rat organic anion transporters. J Pharmacol Exp Ther 2002; 301: 145–151
   PubMed Web of Science ®Google Scholar
• Dutt A, Priebe T S, Teeter L D, Kuo M T, Nelson J A. Postnatal development of organic cation transport and mdr gene expression in mouse kidney. J Pharmacol Exp Ther 1992; 261: 1222–1230
   PubMed Web of Science ®Google Scholar
• Marchi A G, Messi G, Loschi L. Evaluation of changing patterns in children poisonings and prevention. Vet Hum Toxicol 1991; 33: 244–246
   PubMedGoogle Scholar
• Litovitz T L, Flagler S L, Manoguerra A S, Veltri J C, Wright L. Recurrent poisonings among paediatric poisoning victims. Med Toxicol Adverse Drug Exp 1989; 4: 381–386
   PubMedGoogle Scholar